Sun Pharma ka Q3FY26 preview ek familiar story dikhata hai: revenue growth track par hai, lekin profitability gir rahi hai. Analysts ko lagta hai sales ₹14,614.7 crore tak badhegi, jo domestic, emerging markets aur specialty portfolio se aayegi. Lekin, net profit ₹3,040 crore tak gir sakta hai, jo 5.6% ka fall hai. Iska reason U.S. generics market mein pressure aur specialty assets par zyada kharch hai, jis se EBITDA mein lagbhag 3.12% ki girawat aayegi. Yeh Sun Pharma ke strategic pivot ko dikhata hai towards innovation aur specialty products. Stock ₹1,610-₹1,630 ke aas-pas trade kar raha hai, jo 52-week range (₹1,547 se ₹1,850) mein hai. Lagbhag ₹3.82 lakh crore market cap ke saath, Sun Pharma ka TTM P/E ratio kareeb 33.8x hai, jo competitors se premium hai. Dr. Reddy's ka P/E 18.0-18.9x, Cipla ka 20.3-23.6x, aur Lupin ka 22.2-24.1x hai. Halanki Sun Pharma ka bada portfolio premium justify karta hai, margin compression valuation par sawaal uthata hai. Indian pharma sector ₹7-9% grow karne ki ummeed hai FY26 mein. Lekin, Sun Pharma ne pichhle ek saal mein Sensex ko underperform kiya hai (-8.40% vs Sensex ka 8.02% gain). Technical indicators stock ko moving averages ke niche dikha rahe hain. Mojo Score bhi 'Hold' ho gaya hai, lekin average analyst price target ₹1,921.38 jo lagbhag 19.30% upside dikhata hai. Sun Pharma FY26 mein mid-to-high single-digit consolidated topline growth expect karta hai, complex generics aur specialty par focus ke saath. Analysts ka sentiment mixed hai (12 Strong Buy, 19 Buy, 1 Hold, 3 Sell, 1 Strong Sell), par average target price ₹1,921.38 growth ki expectation dikhata hai. Market dekhega ki company specialty investments ko profitable growth mein kaise badalti hai aur generics business ke pressures ko kaise handle karti hai.
Sun Pharma: Specialty Investments Ke Chakkar Mein Revenue Badhne Par Bhi Margins Par Dabav
HEALTHCAREBIOTECH
Overview
Sun Pharma (SUNP.NS) ka Q3FY26 mila-jula rahne ki ummeed hai. Analysts ₹14,614.7 crore revenue mein 6.9% badhotri aur ₹3,040 crore net profit mein 5.6% ki girawat dekh rahe hain. Yeh U.S. generics market mein kamzori aur specialty business mein badhte kharchon ke karan hai. Company ka market cap lagbhag ₹3.82 lakh crore hai aur TTM P/E kareeb 33.8x hai, jo industry peers se zyada hai.
Disclaimer:This content
is for educational and informational purposes only and does not constitute investment, financial, or
trading advice, nor a recommendation to buy or sell any securities. Readers should consult a
SEBI-registered advisor before making investment decisions, as markets involve risk and past performance
does not guarantee future results. The publisher and authors accept no liability for any losses. Some
content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views
expressed do not reflect the publication’s editorial stance.